Ontology highlight
ABSTRACT: Introduction
Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1-month depot for CPP.Methods
This prospective, open-label study had a long-term, observational, follow-up period. Forty-nine females and 6 males were enrolled. Leuprolide acetate depot was administered intramuscularly every 28 days. Height and growth rate during and after treatment until adulthood were measured.Results
Among 30 of 49 females having an adult height (AH) measurement, 29 had target heights available (mean = 163.8 cm) and 27 had pretreatment predicted adult heights (PAHs; mean = 157.4 cm). After treatment, the mean AH at mean age 21.8 years [range 13.7-26.7 years] was 162.5 cm, a mean height gain over baseline PAH of 4.0 cm. The mean height standard deviation score was -0.1 at AH.Conclusions
Treatment of CPP with leuprolide acetate 1-month depot had beneficial effects on growth rate and preservation of AH.Trial registration
ClinicalTrials.gov: NCT00660010.
SUBMITTER: Lee PA
PROVIDER: S-EPMC3159140 | biostudies-literature | 2011
REPOSITORIES: biostudies-literature
Lee Peter A PA Neely E Kirk EK Fuqua John J Yang Di D Larsen Lois M LM Mattia-Goldberg Cynthia C Chwalisz Kristof K
International journal of pediatric endocrinology 20110712 1
<h4>Introduction</h4>Gonadotropin-releasing hormone analogs (GnRHa) are the treatment of choice for CPP. We investigated growth in GnRHa-naïve subjects, treated with leuprolide acetate 1-month depot for CPP.<h4>Methods</h4>This prospective, open-label study had a long-term, observational, follow-up period. Forty-nine females and 6 males were enrolled. Leuprolide acetate depot was administered intramuscularly every 28 days. Height and growth rate during and after treatment until adulthood were me ...[more]